Innoviva (INVA) Non-Current Debt (2010 - 2026)
Innoviva posted quarterly Non-Current Debt of $258.1 million for Q1 2026, up 0.56% year-on-year from $256.7 million in Q1 2025, and little changed on a QoQ basis from $257.7 million in Q4 2025.
Innoviva (INVA) has 14 years of Non-Current Debt data on file, last reported at $258.1 million in Q1 2026.
- For the quarter ending Q1 2026, Non-Current Debt rose 0.56% year-over-year to $258.1 million; the trailing twelve-month figure through Mar 2026 stood at $258.1 million (up 0.56% YoY), and the FY2025 full-year result was $257.7 million, up 0.55% from the prior year.
- Non-Current Debt for Q1 2026 stood at $258.1 million, roughly flat from $257.7 million in the prior quarter.
- Across five years, Non-Current Debt topped out at $447.3 million in Q2 2024 and bottomed at $256.0 million in Q3 2024.
- The 5-year median for Non-Current Debt is $443.7 million (2022), against an average of $357.5 million.
- The widest annual swing landed in 2022, when Non-Current Debt climbed 13.1%; it then plunged 42.57% in 2024.
- A 5-year view of Non-Current Debt shows it stood at $444.2 million in 2022, then grew by 0.46% to $446.2 million in 2023, then tumbled by 42.56% to $256.3 million in 2024, then rose by 0.55% to $257.7 million in 2025, then advanced by 0.14% to $258.1 million in 2026.
- The last three Non-Current Debt figures came in at $258.1 million (Q1 2026), $257.7 million (Q4 2025), and $257.4 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 319.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 105.94 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.99 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Innoviva | 1.60 Bn | 992.84 Mn | 75.83 Mn | 258.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 258.10 Mn |
| Mar 31, 2026 | 258.10 Mn |
| Dec 31, 2025 | 257.73 Mn |
| Dec 31, 2025 | 257.73 Mn |
| Sep 30, 2025 | 257.38 Mn |
| Sep 30, 2025 | 257.38 Mn |
| Jun 30, 2025 | 257.02 Mn |
| Jun 30, 2025 | 257.02 Mn |
| Mar 31, 2025 | 256.67 Mn |
| Mar 31, 2025 | 256.67 Mn |
| Dec 31, 2024 | 256.32 Mn |
| Dec 31, 2024 | 256.32 Mn |
| Sep 30, 2024 | 255.97 Mn |
| Sep 30, 2024 | 255.97 Mn |
| Jun 30, 2024 | 447.28 Mn |
| Jun 30, 2024 | 447.28 Mn |
| Mar 31, 2024 | 446.76 Mn |
| Mar 31, 2024 | 446.76 Mn |
| Dec 31, 2023 | 446.23 Mn |
| Dec 31, 2023 | 446.23 Mn |
| Sep 30, 2023 | 445.72 Mn |
| Sep 30, 2023 | 445.72 Mn |
| Jun 30, 2023 | 445.20 Mn |
| Jun 30, 2023 | 445.20 Mn |
| Mar 31, 2023 | 444.69 Mn |
| Mar 31, 2023 | 444.69 Mn |
| Dec 31, 2022 | 444.18 Mn |
| Dec 31, 2022 | 444.18 Mn |
| Sep 30, 2022 | 443.68 Mn |
| Sep 30, 2022 | 443.68 Mn |
| Dec 31, 2021 | 394.65 Mn |
| Dec 31, 2021 | 394.65 Mn |
| Sep 30, 2021 | 392.30 Mn |
| Sep 30, 2021 | 392.30 Mn |
| Jun 30, 2021 | 389.99 Mn |
| Jun 30, 2021 | 389.99 Mn |
| Mar 31, 2021 | 387.73 Mn |
| Mar 31, 2021 | 387.73 Mn |
| Dec 31, 2020 | 385.52 Mn |
| Dec 31, 2020 | 385.52 Mn |
| Sep 30, 2020 | 383.35 Mn |
| Sep 30, 2020 | 383.35 Mn |
| Jun 30, 2020 | 381.23 Mn |
| Jun 30, 2020 | 381.23 Mn |
| Mar 31, 2020 | 379.15 Mn |
| Mar 31, 2020 | 379.15 Mn |
| Dec 31, 2019 | 377.12 Mn |
| Dec 31, 2019 | 377.12 Mn |
| Sep 30, 2019 | 388.64 Mn |
| Sep 30, 2019 | 388.64 Mn |
| Jun 30, 2019 | 386.68 Mn |
| Jun 30, 2019 | 386.68 Mn |
| Mar 31, 2019 | 384.74 Mn |
| Mar 31, 2019 | 384.74 Mn |
| Dec 31, 2018 | 382.86 Mn |
| Dec 31, 2018 | 382.86 Mn |
| Sep 30, 2018 | 381.00 Mn |
| Sep 30, 2018 | 381.00 Mn |
| Jun 30, 2018 | 486.53 Mn |
| Jun 30, 2018 | 486.53 Mn |
| Mar 31, 2018 | 484.59 Mn |
| Mar 31, 2018 | 484.59 Mn |
| Dec 31, 2017 | 574.36 Mn |
| Dec 31, 2017 | 574.36 Mn |
| Sep 30, 2017 | 578.45 Mn |
| Sep 30, 2017 | 578.45 Mn |
| Jun 30, 2017 | 400.85 Mn |
| Jun 30, 2017 | 400.85 Mn |
| Mar 31, 2017 | 464.60 Mn |
| Mar 31, 2017 | 464.60 Mn |
| Dec 31, 2016 | 708.34 Mn |
| Dec 31, 2016 | 708.34 Mn |
| Sep 30, 2016 | 477.91 Mn |
| Sep 30, 2016 | 477.91 Mn |
| Jun 30, 2016 | 480.88 Mn |
| Jun 30, 2016 | 480.88 Mn |
| Mar 31, 2016 | 483.39 Mn |
| Mar 31, 2016 | 483.39 Mn |
| Dec 31, 2015 | 482.14 Mn |
| Dec 31, 2015 | 482.14 Mn |
| Sep 30, 2015 | 488.98 Mn |
| Sep 30, 2015 | 488.98 Mn |
| Jun 30, 2015 | 483.36 Mn |
| Jun 30, 2015 | 483.36 Mn |
| Mar 31, 2015 | 476.95 Mn |
| Mar 31, 2015 | 476.95 Mn |
| Dec 31, 2014 | 470.53 Mn |
| Dec 31, 2014 | 470.53 Mn |
| Sep 30, 2014 | 450.00 Mn |
| Sep 30, 2014 | 450.00 Mn |
| Jun 30, 2014 | 450.00 Mn |
| Jun 30, 2014 | 450.00 Mn |
| Dec 31, 2010 | 69,000.00 |
| Dec 31, 2010 | 69,000.00 |